We found that cGAS/STING activation in PBMCs, mainly in cytotoxic lymphoid cells, together with rare germline variants in the DDR gene panel, may be a useful tool to predict response to immunotherapy in LC patients but requires further confirmation in a larger number of patients. This evidence concerns the gene STING1 and laryngotracheoesophageal cleft.